Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Toxin And Spasticity

E. C. Davis, M. Barnes
Published 2000 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The clinical effects of botulinum toxin have been recognised since the end of the 19th century. It is the most potent neurotoxin known and it is produced by the gram negative anaerobic bacterium Clostridium botulinum. The paralytic effect of the toxin is due to blockade of neuromuscular transmission.1 Injection into a muscle causes chemodenervation and local paralysis and this effect has led to the development of the toxin as a therapeutic tool. It is now used clinically for a wide range of conditions,2particularly focal dystonias, and increasingly for spasticity. This paper reviews the mode of action of botulinum and focuses on its use in the management of spasticity. There are seven immunologically distinct serotypes of botulinum toxin (labelled A-G). This review concentrates on the only type in routine clinical use—type A (BTX-A). Currently, type B,3 4type C,5 and type F6-8are being investigated for clinical use and type B may be available in the near future. Botulinum toxin acts at the neuromuscular junction by inhibiting the release of acetylcholine. It acts selectively on peripheral cholinergic nerve endings causing chemical denervation after the binding, internalisation, and activation of the toxin at the neuromuscular junction. The toxin is synthesised as a relatively inactive single polypeptide chain. Selective high affinity binding of BTX-A occurs at the neuromuscular junction. After internalisation, it is activated when its structure is modified by cleavage of the disulfide bond linking the light and heavy chain. The N terminal of the heavy chain then promotes penetration and translocation of the light chain across the endosomal membrane into the cytosol. This then interacts with, and cleaves the fusion protein SNAP 25 (synaptosomal associated protein) inhibiting the calcium mediated release of acetylcholine from the presynaptic nerve terminal.9 10 Nerve sprouting and muscle re-innervation …
This paper references
10.1136/jnnp.64.5.577
Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A
M. Houser (1998)
10.1212/WNL.45.9.1743
Response and immunoresistance to botulinum toxin injections
J. Jankovic (1995)
10.1016/S0140-6736(86)92070-2
DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS
J. C. Tsui (1986)
A randomised , double blind , placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemi - paretic patients
P Burbaud (1996)
Management of spasticity. Age Ageing 1998;27:239–45
MP Barnes (1998)
10.1016/0966-6362(95)01054-8
Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: a 3-dimensional motion analysis study
D. Sutherland (1996)
10.1212/WNL.46.5.1306
Botulinum toxin type A in the treatment of upper extremity spasticity
D. Simpson (1996)
10.1007/S11940-000-0037-7
Blepharospasm and hemifacial spasm
D. Boghen (2000)
10.1053/APMR.2001.21843
Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: a comparative study between a home and a clinic treatment service.
J. Whitaker (2001)
Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients.
B. Schurch (1996)
10.1001/ARCHNEUR.1986.00520040060020
Botulinum toxin in the management of blepharospasm.
J. Dutton (1986)
10.1016/S0304-3940(97)13448-6
Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human
R. Eleopra (1997)
Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diVusion
R Eleopra (1996)
10.1212/WNL.50.5.1463
A radioimmunoprecipitation assay for antibodies to botulinum A
J. Palace (1998)
10.1212/WNL.41.8.1185
Botulinum toxin treatment of tremors
J. Jankovic (1991)
10.1038/sj.sc.3100517
Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease
H. Petit (1998)
Botulinum A toxin as a treatment of detrusorsphincterdyssynergia : a prospective study in 24 spinal cord injury patients
B Schurch (1996)
Botulinum toxin for spasms and spasticity in the lower extremities Therapy with botulinum toxin
R Benecke (1994)
Botulinum toxin type A and short term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomised, double blind, placebo controlled trial
S Hesse (1998)
10.1097/01241398-199307000-00013
Management of Cerebral Palsy with Botulinum‐A Toxin: Preliminary Investigation
L. Koman (1993)
10.1136/bmj.297.6648.616
Botulinum toxin treatment of spasmodic torticollis.
R. Stell (1988)
Disorders of the pelvic floor Botulinum toxin treatment
Cj Fowler (1995)
10.1136/PGMJ.65.762.208
Effect of treatment with botulinum toxin on spasticity.
T. K. Das (1989)
10.1136/jnnp.56.5.526
The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.
R. Whurr (1993)
10.1016/S0887-8994(97)00164-1
Use of botulinum toxin injection in 17 children with spastic cerebral palsy.
V. Wong (1998)
National Institutes of Health Consensus Development Conference. Clinical use of botulinum toxin
(1991)
Botulinum toxin treatment for cranio-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm
J Jankovic (1990)
Botulinum toxin type A in the treatment of upper extremity spasticity: a randomised, double blind, placebo controlled trial
DM Simpson (1996)
10.1001/ARCHDERM.134.3.301
Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin.
M. Naumann (1998)
Focal hyperhidrosis. Arch Dermatol 1998;134:301–4
M Naumann (1998)
10.1136/jnnp.67.1.90
Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases
K. Bhatia (1999)
10.1212/WNL.45.4.712
Botulinum toxin A for spasticity, muscle spasms, and rigidity
M. Grazko (1995)
10.1212/WNL.50.6.1624
Mouse bioassay versus Western blot assay for botulinurn toxin antibodies Correlation with clinical response
P. Hanna (1998)
Treatment of detrusorsphincterdyssynergia with botulinum A toxin : a double blind study
DD Dykstra (1990)
The neuropsychiatric inventory : comprehensive assessment of psychopathology in dementia
S MegaM (1994)
Botulinum A toxin therapy: neutralizing antibodies: therapeutic consequences
H Goschel (1997)
10.1016/0007-1226(93)90203-N
Botulinum A chemodenervation: a new modality in cerebral palsied hands.
S. Wall (1993)
10.1007/978-3-319-17855-4_10
The management of spasticity.
Jonathan Birns (1972)
10.1136/jnnp.53.8.633
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.
J. Jankovic (1990)
10.21236/ada094643
The action of batulinum toxin at the neuromuscular junction.
L. Sellin (1981)
10.1111/j.1469-8749.1997.tb07471.x
Visual Evoked Potentials a Diagnostic Test for Migraine Headache in Children
I. Abu-Arafeh (1997)
Botulinum A toxin treatment for detrusor - sphincter - dyssynergia in
H Petit
Use of botulinum toxin in the treatment of achalasia Botulinum toxin in the treatment of glabel - lar frown lines and other facial wrinkles
LS Miller
10.1212/WNL.45.3.506
Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm
T. Mezaki (1995)
10.1016/S0022-5347(17)56987-6
Detrusor-sphincter dyssynergia.
E. Mcguire (1979)
10.3109/9780203450321-49
Therapy with botulinum toxin
J. Jankovic (1994)
10.1111/J.1467-8705.1981.TB02321.X
Government health warning
E. Bartlett (1981)
10.1288/00005537-199106000-00010
Double‐blind controlled study of botulinum toxin in adductor spasmodic dysphonia
Daniel D. Truong (1991)
10.1136/jnnp.57.11.1321
Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients.
S. Hesse (1994)
Generalised botulismlike syndrome after intramuscular injections of botulinum toxin type A : a report of two cases
Bakheit AMO (1997)
[Local injection treatment with botulinum toxin A in severe arm and leg spasticity].
A. Konstanzer (1993)
Comparison of therapeutic eYcacies of type A and F botulinum toxins for blepharospasm: a double blind controlled study
T Mezaki (1995)
The neuropsychiatric inventory : comprehensive assessment of psychopathology in dementia
W Jagust (1994)
10.1212/WNL.47.4.939
Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury
S. Yablon (1996)
10.1212/WNL.38.11.1780
Neuromuscular effects distant from the site of botulinum neurotoxin injection
Richard K. OIney (1988)
10.1111/j.1469-8749.1994.tb11864.x
BOTULINUM TOXIN IN THE MANAGEMENT OF THE LOWER LIMB IN CEREBRAL PALSY
A. Cosgrove (1994)
10.1002/ANA.410310122
Treatment of spasticity with botulinum toxin
G. Borodic (1992)
10.1002/(SICI)1097-4598(199604)19:4<488::AID-MUS9>3.0.CO;2-8
Extrafusal and intrafusal muscle effects in experimental botulinum toxin‐A injection
R. Rosales (1996)
Botulinum toxin type A and short term B TOONE Department of Psychiatry, King's College Hospital
S Hesse
10.1016/S0161-6420(97)30220-6
Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections.
J. Price (1997)
10.1016/S0003-9993(98)90020-X
Axillary hyperhidrosis: treatment with botulinum toxin A.
I. Odderson (1998)
10.1191/026921598668275996
Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial
S. Hesse (1998)
10.1046/J.1365-2133.1998.02151.X
Optimizing botulinum toxin therapy for hyperhidrosis
Heckmann (1998)
10.1001/ARCHNEUR.1996.00550070055012
Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients.
S. Pullman (1996)
10.1177/026921559701100102
Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients
C. Sampaio (1997)
Local botulinum toxin in the treatment of spastic foot drop
R Dengler (1992)
10.12968/BJTR.1999.6.9.13943
Botulinum toxin in spasticity management
A. Ward (1999)
10.1136/jnnp.59.6.601
Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.
G. Sheean (1995)
10.1212/WNL.43.4.834
Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia
J. Jankovic (1993)
Comparison of therapeutic e Ycacies of type A and F botulinum toxins for blepharospasm : a double blind controlled study
T Mezaki (1995)
10.1002/MDS.870090106
Histologic assessment of dose‐related diffusion and muscle fiber response after therapeutic botulinum a toxin injections
G. Borodic (1994)
10.1016/S0140-6736(88)90554-5
CLINICAL USE OF BOTULEMUM TOXIN
J. Elston (1988)
10.1136/jnnp.61.3.265
A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients.
P. Burbaud (1996)
10.1136/jnnp.66.5.612
Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies
P. Hanna (1999)
Botulinum toxin type B in the treatment of cervical dystonia : a pilot study
MF Lew (1995)
Botulinum toxin treatment in the facial muscles of humans : evidence of an action in untreated near muscles by peripheral local di V usion
GE Borodic (1996)
10.1176/AJP.154.12.1676
Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study.
P. Woodruff (1997)
10.1038/265160a0
Cμ4 domain of IgM has cytophilic activity for human lymphocytes
JAN D. Conradie (1977)
Therapeutic uses of type F botulinum toxin [ letter ]
J Blasi (1992)
The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia
J LCummings (1994)
10.1007/978-1-4471-3456-5_18
Disorders of the Pelvic Floor
P. F. Schofield (1993)
Histologic assessment of doserelated di V usion and muscle fiber response after therapeutic botulinum A toxin injections
R Stell (1994)
10.1212/WNL.44.12.2308
The Neuropsychiatric Inventory
J. Cummings (1994)
10.1046/j.1526-4610.1997.3704253.x
Botulinum Toxin Injection for Cervicogenic Headache
D. Hobson (1997)
10.1159/000016845
Use of Botulinum Toxin in the Treatment of Achalasia
T. Schiano (1998)
Therapeutic uses of type F botulinum toxin [letter
CL Ludlow (1992)
Quantitative assessment of botulinum toxin in 43 patients with head tremor
J Wissel (1997)
Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study.
D. Dykstra (1990)
Oromandibular dystonia: Treatment of 96 patients with botulinum toxin A
M. Brin (1994)
Medico-legal reports.
McCormack Mp (1993)
Botulinum toxin for spasms and spasticity in the lower extremities
R. Benecke (1994)
10.1136/jnnp.69.2.161
Acoustic neuroma surgery as an interdisciplinary approach: a neurosurgical series of 508 patients
J. Tonn (2000)
10.1053/hn.1999.v121.a91263
Hearing preservation in solitary vestibular schwannoma surgery using the retrosigmoid approach
E. Myers (1999)
10.1212/WNL.37.4.616
Botulinum A toxin for cranial‐cervical dystonia
J. Jankovic (1987)
10.1006/exnr.1997.6580
Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences
H. Göschel (1997)
10.1113/jphysiol.1949.sp004364
The action of botulinum toxin on the neuro‐muscular junction
A. Burgen (1949)
10.1002/MDS.870060210
Treatment of idiopathic spasmodic torticollis with botulinum toxin a: A double‐blind study on twenty‐three patients
I. Lorentz (1991)
Oromandibular dystonia : treatment of 96 patients with botulinum toxin type A . In : Jankovic J , Hallett M , eds . Therapy with botulinum toxin
MF Brin (1994)
Botulinum toxin in the treatment of writer’s cramp: a double blind study
JKC Tsui (1993)
disease
P Gallien (1998)
10.3928/0191-3913-19800101-06
Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.
A. B. Scott (1980)
10.1046/j.1365-2133.1997.d01-1233.x
Double‐blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms
P. Schnider (1997)
10.1016/S0003-9993(96)90042-8
Botulinum toxin for spasticity and athetosis in children with cerebral palsy.
J. Gooch (1996)
Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse.
A. Cosgrove (1994)
10.1016/S0003-9993(98)90050-8
Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin.
P. Gallien (1998)
10.1136/jnnp.62.2.198
Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases.
A. Bakheit (1997)
10.1136/JNNP.64.3.419
Botulinum toxin type A in the treatment of upper limb spasticity among patients with traumatic brain injury
G. Pavesi (1998)
10.1136/jnnp.69.2.167
Cerebral correlates of psychotic symptoms in Alzheimer's disease
M. Mega (2000)
Strabismus and other ocular motility disorders
JP Lee (1995)
Botulinum toxin: dangerous errors [letter
MF Brin (1993)
Botulinum toxin in the treatment of glabellar frown lines and other facial wrinkles
A Carruthers (1994)
Botulinum toxin type A in the treatment of upper limb spasticity among patients with traumatic brain injury [letter
G Pavesi (1998)
10.1212/WNL.39.1.80
Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis
D. Gelb (1989)
10.1002/MDS.870120627
DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1
C. Sampaio (1997)
10.1002/MDS.870090604
Botulinum toxin a injections for the treatment of hand tremors
R. Trosch (1994)
10.1002/ANA.410280407
Treatment of spasticity with botulinum toxin: A double‐blind study
B. Snow (1990)
The neuropsychiatric inventory : comprehensive assessment of psychopathology in dementia
L CummingsJ (1994)
10.1136/jnnp.59.5.562-a
Treatment of chronic limb spasticity with botulinum toxin A.
B. Bhakta (1995)
10.1212/WNL.45.4.822
Botulinum toxin treatment of essential head tremor
R. Pahwa (1995)
10.1016/0002-9394(88)90590-9
Treatment of acquired nystagmus with botulinum A toxin.
E. Helveston (1988)
10.1097/00000542-199403000-00041
Treatment of myofascial pain with botulinum A toxin.
M. Acquadro (1994)
Botulinum toxin in spasmodic torticollis.
J. Tsui (1988)
Botulinum toxin type B in the treatment of cervical dystonia : a pilot study
Tsui JKC (1995)
Botulinum A toxin treatment for detrusorsphincterdyssynergia in spinal cord disease
H Petit (1998)
10.1016/S0022-5347(01)66376-6
Botulinum-A Toxin as a Treatment of Detruosor-Sphincter Dyssynergia: A Prospective Study in 24 Spinal Cord Injury Patients
B. Schurch (1996)
10.1002/MDS.870120516
Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor
J. Wissel (1997)
10.1002/MDS.870110306
A randomized, double‐blind, placebo‐controlled study to evaluate botulinum toxin type A in essential hand tremor
J. Jankovic (1996)
10.1002/MDS.870080411
Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A
P. E. Greene (1993)
Focal hyperhidrosis
M Naumann (1998)
Botulinum toxin therapy for upper limb spasticity: preliminary results
S Hesse (1992)
10.1097/00001577-199801020-00013
Botulinum Toxin A in the Hemiplegic Upper Limb: A Double‐blind Trial
L. Arens (1997)
10.1136/jnnp.64.1.6
A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox®in the treatment of cervical dystonia
T. Odergren (1998)
10.1056/NEJM199201303260516
Therapeutic use of type F botulinum toxin.
C. Ludlow (1992)
10.1136/jnnp.61.1.30
Use of botulinum toxin in stroke patients with severe upper limb spasticity.
B. Bhakta (1996)
10.1016/0030-4220(92)90395-7
Temporomandibular joint dysfunction. Connective tissue variations in skin biopsy and mitral valve function.
L. Westling (1992)
10.1212/WNL.38.6.909
Longitudinal studies of regional cerebral metabolism in Alzheimer's disease
W. Jagust (1988)
10.1136/jnnp.64.6.751
Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases
S. Jitpimolmard (1998)
10.1212/WNL.50.5.1461
Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia
J. Brans (1998)
10.1212/WNL.49.3.701
Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
M. Lew (1997)
10.1097/00002060-199807000-00020
Botulinum toxin treatment of lumbrical spasticity: a brief report.
D. Palmer (1998)
Botulinum toxin treatment for craniocervical dystonia , spasmodic dysphonia , other focal dystonias and hemifacial spasm
J Jankovic (1990)
10.1016/S0003-9993(98)90068-5
Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke.
F. Reiter (1998)
10.1016/S0003-9993(96)90015-5
Botulinum toxin A in the treatment of spasticity: functional implications and patient selection.
S. H. Pierson (1996)
Double blind study of botulinum toxin in spasmodic torticollis: Lancet 1986;ii:245–7
JKC Tsui (1986)
10.1097/01241398-199805000-00006
Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial.
I. Corry (1998)
10.1093/BRAIN/121.4.547
Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia.
W. Dauer (1998)
10.1007/BF00812153
Local botulinum toxin in the treatment of spastic drop foot
R. Dengler (2004)
10.1038/365160A0
Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25
J. Blasi (1993)
Botulinum toxin : dangerous errors [ letter ]
T Odergren (1993)
Botulinum toxin A treatment in spasticity of arm and leg
A Konstanzer (1993)
Botulinum toxin in the treatment of writer ’ s cramp : a double blind study
Tsui JKC (1993)
Botulinum toxin type B in the treatment of cervical dystonia: a pilot study
JKC Tsui (1995)
Botulinum toxin: dangerous errors
M F Brin
10.1097/01241398-199405000-00005
Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial.
L. Koman (1994)
10.1056/NEJM199104253241707
Therapeutic uses of botulinum toxin.
J. Jankovic (1991)
Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients.
P. A. Cullis (1998)
10.1212/WNL.46.4.1158
Botulinum toxin treatment in the facial muscles of humans
R. Eleopra (1996)



This paper is referenced by
Spasticity Evaluation of Hemiparetic Limbs in Stroke Patients before Intervention by Using Portable Stretching Device and EMG
Y. Wu (2004)
10.1080/16501960310010151
Botulinum toxin--mechanisms of action and clinical use in spasticity.
M. Barnes (2003)
10.1016/J.APMR.2005.03.019
The use of a portable muscle tone measurement device to measure the effects of botulinum toxin type a on elbow flexor spasticity.
J. Chen (2005)
10.12968/BJNN.2008.4.8.30805
Management of spasticity: A brief overview of educational and pharmacological therapies
J. Birns (2008)
Assessment of functional improvement in the hemiparetic arm following focal rehabilitation intervention
S. Ashford (2012)
10.1053/APMR.2003.50001
Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection.
E. Hurvitz (2003)
10.1016/J.APMR.2006.12.031
Motor points for the neuromuscular blockade of the subscapularis muscle.
T. P. Harrison (2007)
10.1007/s00415-004-0297-3
Botulinum toxin in post-stroke patients: stiffness modifications and clinical implications
G. Miscio (2004)
10.4172/2329-6895.1000134
Restoring Motor functions in Spinal cord injury, Hemiplegic Cerebral Palsy, and Stroke by Botulinum toxin-induced Synaptic Competitive-Learning Therapy
R. Krishnan (2013)
10.1111/j.1469-8749.2006.tb01309.x
AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections
N. Lannin (2006)
10.1016/J.APMR.2003.08.081
The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation.
C. A. Johnson (2004)
10.1007/PL00007851
Efficacy of botulinum toxin A in upper limb function of hemiplegic patients
M. Rousseaux (2002)
The most effective interventions to decrease muscle tone and improve upper extremity function in elderly stroke patients with arm spasticity
Lisa Munz (2009)
Botulinumtoksin A – effekt på spastisitet
T. Smedal (2001)
10.1017/CBO9780511545047.013
The Circuitry of the Human Spinal Cord: The pathophysiology of spasticity and parkinsonian rigidity
E. Pierrot-Deseilligny (2005)
10.1080/09602010244000381
Pain following traumatic brain injury: Assessment and management
Stephen Tyrer (2003)
10.1186/1749-799X-4-34
Botulinum toxin type A injections for the management of muscle tightness following total hip arthroplasty: a case series
A. Bhave (2009)
10.1002/14651858.CD010169
Treatment for dysphagia (swallowing difficulties) in hereditary ataxia syndromes
A. Vogel (2012)
i Botulinum Toxin A for Upper and Lower Limb Spasticity : A Systematic Review Technology Report
A. Mccormick (2005)
10.1016/S1047-9651(18)30035-4
Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders.
S. Yablon (2001)
10.1136/jnnp.2004.035972
Clinical management of spasticity
A. Thompson (2005)
10.1002/14651858.CD010169.pub2
Treatment for dysphagia (swallowing difficulties) in hereditary ataxia.
A. Vogel (2015)
Zmiany czynności kory ruchowej mózgu po leczeniu botuliną u pacjentów ze stwardnieniem rozsianym i spazmem kończyn dolnych
Pavel Hok (2011)
10.1201/B21452-6
Focal Treatments, Including Botulinum Toxin
Rachel Farrell (2016)
THE IMPACT OF FUNCTIONAL ELECTRICAL STIMULATION TO THE LOWER LEG AFTER A SINGLE BOTULINUM TOXIN INJECTION IN CHILDREN WITH A SPASTIC EQUINUS GAIT DUE TO CEREBRAL PALSY
A. Seifart (2008)
10.1109/IEMBS.2009.5332735
Reduction of the onset response in high frequency nerve block with amplitude ramps from non-zero amplitudes
N. Bhadra (2009)
10.1080/00207450590956576
BOTULINUM TOXIN: FROM SPASTICITY RELIEVER TO A NEUROMOTOR RE-LEARNING TOOL
R. Krishnan (2005)
10.1159/000052817
Spasticity: A Rehabilitation Challenge in the Elderly
M. Barnes (2001)
10.1589/jpts.30.902
Effect of combined rehabilitation program with botulinum toxin type A injections on gross motor function scores in children with spastic cerebral palsy
Abeer Flemban (2018)
Contribuição da amplitude de movimento articular do joelho na marcha de crianças com paralisia cerebral espástica
R. A. Batistela (2008)
Axonale Integrität corticospinaler Projektionsbahnen zur oberen Extremität bei Patienten mit reiner hereditärer spastischer Paraplegie
Tim Optenhoefel (2013)
Estudo retrospectivo do tratamento fisioterapêutico de um paciente portador de AVC, após aplicação de toxina botulínica
Andreza Maria Luzia Baldo de Souza (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar